Verve Therapeutics' Stock Falls 40% as Analysts Question Safety of Cholesterol-cutting Gene-editing Treatment
Verve Therapeutics' Stock Falls 40% as Analysts Question Safety of Cholesterol-cutting Gene-editing Treatment
由於分析師質疑降膽固醇基因編輯療法的安全性，Verve Therapeutics的股價下跌40％
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊